SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October
26, 2015
Intellect
Neurosciences, Inc.
(Exact
Name Of Registrant As Specified In Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
| 333-128226 |
|
20-8329066 |
| (Commission
File Number) |
|
(I.R.S.
Employer Identification No.) |
| |
|
|
550
Sylvan Ave., Suite 101
Englewood
Cliffs, New Jersey |
|
07632 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
(201)
608-5101
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
8.01. Other Events.
On
October 26, 2015, Intellect Neurosciences, Inc. (the “Company”) issued a press release regarding the engagement of
Troy Rohn, PhD as lead Scientific Advisor to the Company on its TauC3 Antibody Program.
A
copy of the press release that discusses this matter is filed as Exhibit 99.1 to, and incorporated by reference in, this report.
The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act
of 1933, except as shall be expressly set forth by specific reference in any such filing.
The following
exhibit is furnished as part of this Report on Form 8-K:
| Exhibit |
|
Description |
| |
|
|
| 99.1 |
|
Press Release dated October 26,
2015 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Dated: October 26, 2015 |
INTELLECT NEUROSCIENCES, INC. |
| |
|
|
| |
By: |
/s/ Elliot Maza |
| |
Name: Elliot Maza |
| |
Title: Chief Executive Officer |
Exhibit 99.1
Intellect
Neurosciences, Inc. Engages Troy Rohn, PhD as Lead Scientific Advisor for TauC3 Antibody Program
NEW
YORK, October 26, 2015 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTC: ILNS) a biopharmaceutical company engaged
in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative
conditions, announced today that it has appointed Dr. Troy Rohn, Professor, Department of Biological Sciences, Boise State University,
Boise, Idaho, as lead scientific advisor. Dr. Rohn has agreed to assist the company in shaping and guiding the company’s
TauC3 antibody program, and in particular, to identify one or more orphan diseases in which TauC3 is an appropriate target and
for which the company’s TauC3 antibody may be an effective therapeutic agent.
Dr.
Rohn graduated in 1990 from the University of California at Davis with a B.S. in Physiology. He received his Ph.D. in Pharmacology
from the University of Washington, Seattle in 1994. His interests include the role of apoptosis in neurodegenerative diseases.
Dr. Rohn conducted Postdoctoral studies at UC Irvine at the Institute of Brain Aging and Dementia under the direction of Dr. Carl
Cotman. Dr. Rohn continues to collaborate extensively with UC Irvine and in addition with Dr. Eliezer Masliah at UC San Diego.
The
primary focus of Dr. Rohn’s laboratory at Boise State University is the research of neurodegenerative diseases, including
Alzheimer’s disease, Parkinson’s disease, Pick’s disease, frontal temporal dementia and vascular dementia. Dr.
Rohn has conducted numerous experiments with affinity-purified tau caspase cleavage antibodies and has written extensively about
the TauC3 antibody, developed by Lester Binder’s group at Northwestern University, which is under license to Intellect.
Elliot
Maza, Chairman and CEO of Intellect, commented, “We are privileged and delighted that Dr. Rohn has agreed to join Intellect
as lead scientific advisor. Dr. Rohn is uniquely capable to help us target our Tau3 antibody to one or more rare diseases. I look
forward to working with him closely as we adjust the company’s research focus exclusively on rare neurodegenerative diseases.”
Dr.
Rohn commented, “I am honored to assist Intellect meet its drug discovery and commercialization objectives. I am impressed
by the company’s strong science and commitment to advancing the research of caspase cleaved Tau and its role in neurodegenerative
diseases.”
About
Intellect Neurosciences, Inc.
Intellect
Neurosciences, Inc. is biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents
for the treatment and prevention of rare neurodegenerative conditions, collectively known as proteinopathies. Our compounds under
development include OX1, a high affinity, copper binding molecule that protects the body against free radicals. OX1 is licensed
to Shire plc, which recently completed a single ascending dose Phase 1 study to evaluate the safety, tolerability and PK/PD of
OX1 (renamed by Shire as “SHP622”) in subjects with FA. Details of the study, entitled, “A Phase 1, Randomized,
Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects with Friedreich’s Ataxia”, may be found
at: www.clinicaltrials.gov, identifier NCT01898884. For more information, please visit www.intellectns.com.
Safe
Harbor Statements Regarding Forward Looking Statements
The
statements in this letter made by representatives of Intellect Neurosciences relating to matters that are not historical facts,
including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency
of Intellect's cash and other capital resources, the continued development by Shire of SHP622 or its determination to seek Orphan
Drug designation for the pharmaceutical product of SHP622 are forward-looking statements that involve risks and uncertainties,
including, but not limited to, the likelihood that actual performance or results could materially differ, that future research
will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United
States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to
update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak
only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks
and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's
Annual Report on Form 10-K (file no. 333-128226) filed on October 13, 2015.
For
further information contact:
David
Zazoff
MDM
Worldwide Solutions, Inc.
264
W 40th St, #602,
New
York, NY 10018
(212)
643-0417